RxSightinc. Provides Earnings Guidance for Preliminary Unaudited Fourth Quarter 2023 , Preliminary Unaudited Fiscal Year 2023 and for Full-Year 2024
January 07, 2024 at 10:00 am
Share
RxSightInc. provided earnings guidance for Preliminary unaudited fourth quarter 2023, Preliminary unaudited fiscal year 2023 and for full-year 2024. For the period, company expeCts Preliminary unaudited fourth quarter 2023 revenue is expected to be approximately $28.6 million, representing growth of approximately 78% compared to the prior year period.
For Preliminary unaudited 2023 fiscal year revenue is expected to be approximately $89.1 million, representing growth of approximately 82% compared to the prior year.
For 2024, company expects revenue of $128.0 million to $135.0 million, reflecting growth of approximately 44% to 52% over 2023. The company currently estimates the full-year 2024 gross profit margin to be in the 65% - 67% range.
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Companyâs RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patientâs vision outcomes.
RXSIGHT, INC. 
